Sentences with phrase «lung cancer patients who»

In a clinical trial, lung cancer patients who used an app developed by an Israel - based company lived seven months longer than patients who only received standard care.

Cancer Research UK scientists in Oxford are trialling an experimental drug to treat lung cancer patients who have stopped responding to initial chemotherapy treatment.

The international early Phase II trial led by a team based at the Oxford Cancer Research Centre will trial the experimental drug called LY2181308 with advanced non-small cell lung cancer patients who no longer respond to platinum chemotherapy - the standard initial treatment for this group.

Professor Jean - Charles Soria, Chairman of the Drug Development Department at Gustave Roussy Cancer campus, France, will tell the Symposium: «Currently, there are no approved targeted therapies for mutant EGFR lung cancer patients who develop the T790M mutation, which means their disease inevitably will get worse.

For example, lung cancer patients who were injected with killed M. vaccae reported better quality of life and less nausea and pain.

Additionally, lung cancer patients who have high levels of YAP1 in their tumors are more likely to have a poorer prognosis than patients with low levels of YAP1.

«What is particularly encouraging is that we are now able to select, based on features in the tumor, approximately a quarter of advanced lung cancer patients who can receive immunotherapy as their initial treatment.

«Today, we had a lung cancer patient who wanted a clown Mavis, and one for a bride and groom who are battling cancer.»

Not exact matches

Related Articles: Merck's Keytruda held back by docs who don't want to wait for diagnostics Bristol's Opdivo - Yervoy combo ups response rates in first - line lung cancer patients Roche's Tecentriq bursts onto immuno - oncology scene, with Merck and BMS in its sights Bristol - Myers» new Opdivo ad touts biomarker advantage over Merck's Keytruda Merck's Keytruda lines up its survival data for stepped - up battle with BMS» Opdivo

«We feel it'll be able to help kill cancer cells in 80 percent of breast cancer patients,» said Dr. Olson, who added that their antibody has the potential to help kill lung, colon, prostate and other cancer cells, too.

Geoff Oxnard, an assistant professor of medicine at Dana - Farber Cancer Institute and Harvard Medical School in Boston and one of Paweletz's collaborators, remarks that «I had a hospitalized patient last week, she's sick with metastatic lung cancer, and she's exactly the kind of patient who might have an [epithelial growth factor receptor (EGFR)-RSB- mutation, but I simply didn't have enough tissue to ask those questions yet.&Cancer Institute and Harvard Medical School in Boston and one of Paweletz's collaborators, remarks that «I had a hospitalized patient last week, she's sick with metastatic lung cancer, and she's exactly the kind of patient who might have an [epithelial growth factor receptor (EGFR)-RSB- mutation, but I simply didn't have enough tissue to ask those questions yet.&cancer, and she's exactly the kind of patient who might have an [epithelial growth factor receptor (EGFR)-RSB- mutation, but I simply didn't have enough tissue to ask those questions yet.»

Urbanic said the overall findings of the study suggest that there are some patients with recurrent lung cancers who can be treated with another definitive course of radiation therapy and still have a chance at a cure.

Both of the researchers, who are in their early forties, said they were motivated by the need to give lung cancer patients better options.

The Chinese trial will enrol patients who have metastatic non-small cell lung cancer and for whom chemotherapy, radiation therapy and other treatments have failed.

One, in which Dr. Weiss was the senior author, highlighted the extended survival of metastatic small cell lung cancer (SCLC) patients who received statins.

In addition, the study showed that the 5 - year survival rate for selected older patients with advanced lung cancer who were treated with surgical therapy was 29.9 % for Stage III and 26.7 % for Stage IV.

Among patients who have this type of lung cancer, nearly one in three will carry a particular genetic mutation on their cancer cells.

Fewer than half of all patients who undergo surgery for lung cancer survive as long as 5 years.

The GTSD data included 37,009 records for patients 65 years of age and older who underwent lung cancer surgery between 2002 and 2012.

Among patients with non-small cell lung cancer (NSCLC) fueled by ALK gene alterations who were being treated with crizotinib (Xalkori), a decrease in the number of circulating tumor cells (CTCs) harboring increased copies of the ALK gene over the first two months of treatment was associated with increased progression - free survival.

Phase I / II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK + non-small cell lung cancer (NSCLC), with 58 of 78 ALK + patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor.

Combining radiation therapy with chemotherapy for patients with limited metastatic non-small cell lung cancer (NSCLC) may curb disease progression dramatically when compared to NSCLC patients who only receive chemotherapy, according to a new randomized phase II clinical trial reported today at the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO).

After a median follow - up of 11 months, 11 of the 13 patients who responded remain on the study, including one patient who had non-small cell lung cancer (NSCLC) with a ROS1 gene fusion who has had a complete response that has been maintained for more than two years.

Now doctors have investigated the use of crizotinib in patients with ALK positive lung cancer who have not yet received any chemotherapy treatment.

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred treatment option for patients with advanced non-small cell lung cancer (NSCLC) who have mutations in the EGFR gene.

Trinh and his colleagues used Surveillance, Epidemiology, and End Results Program (SEER) data to look at more than 2.5 million Asian American patients who were diagnosed with lung, breast, prostate or colorectal cancer (the three leading causes of cancer - related mortality within each gender) between 1991 and 2007.

«If you look at a set of lung cancer patients, like we did in the paper, who develop brain metastases, they all have those two genes in their primary lung cancer,» said Sheila Singh, the study's supervisor, associate professor at the Michael G. DeGroote School of Medicine, scientist with the Stem Cell and Cancer Research Institute at McMaster University and neurosurgeon at McMaster Children's Hoscancer patients, like we did in the paper, who develop brain metastases, they all have those two genes in their primary lung cancer,» said Sheila Singh, the study's supervisor, associate professor at the Michael G. DeGroote School of Medicine, scientist with the Stem Cell and Cancer Research Institute at McMaster University and neurosurgeon at McMaster Children's Hoscancer,» said Sheila Singh, the study's supervisor, associate professor at the Michael G. DeGroote School of Medicine, scientist with the Stem Cell and Cancer Research Institute at McMaster University and neurosurgeon at McMaster Children's HosCancer Research Institute at McMaster University and neurosurgeon at McMaster Children's Hospital.

«This study demonstrates the value of testing lung cancer tissue for an ALK rearrangement, and it underscores the potential of cancer genomics to target cancer treatments to each patient,» says the study's senior author, Pasi A. Jänne, MD, PhD, who is the director of the Lowe Center for Thoracic Oncology of Dana - Farber.

«The prevalence of comorbidities is higher in older lung cancer patients than patients who are younger,» said K.M. Monirul Islam, M.D., Ph.D., an assistant professor in the department of epidemiology at the University of Nebraska Medical Center College of Public Health.

Islam and colleagues found that among patients with localized lung cancer, those with one comorbidity had a 30 percent higher risk of mortality compared with those who had no comorbidity.

«Pathologists who specialize in molecular diagnostics and lung cancer collaborated to create the guideline to minimize variation and provide greater precision in the care of patients.»

The proportion of patients with lung cancer who smoked more than 30 pack - years declined, and the proportion of former smokers, especially those who quit smoking more than 15 years ago, increased.

Lu's team then cultured the edited cells, increasing their number, and injected them back into the patient, who has metastatic non-small-cell lung cancer.

To investigate why checkpoint inhibitors so often stop working, Velculescu; Valsamo Anagnostou, M.D., Ph.D., instructor of oncology at the Johns Hopkins University School of Medicine; Kellie N. Smith, Ph.D., a cancer immunology research associate at the Johns Hopkins University School of Medicine; and their colleagues at the Bloomberg ~ Kimmel Institute for Cancer Immunotherapy studied tumors of four patients with non-small cell lung cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-cancer immunology research associate at the Johns Hopkins University School of Medicine; and their colleagues at the Bloomberg ~ Kimmel Institute for Cancer Immunotherapy studied tumors of four patients with non-small cell lung cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-Cancer Immunotherapy studied tumors of four patients with non-small cell lung cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-CTLA4.

If this is true, then immunocheckpoint blockade combination with EGFR tyrosine kinase inhibitors is a major path towards improving outcome of patients who have EGFR - mutant non-small-cell lung cancer.»

Among lung cancer patients; suicide SMR was higher in males (SMR = 8.8), Asians (SMR = 13.7), widowed patients (SMR = 11.6), older patients (70 - 75 years; SMR = 12), patients with undifferentiated tumors (SMR 8.6) or small cell lung carcinoma (SCLC) histology (SMR = 11.2), patients presenting with metastatic disease (SMR = 13.9) and in patients who refused to receive surgical treatment (SMR = 13).

The difference with Xalkori is that a test exists to identify that slim percentage of lung cancer patients (about 8,000 people in the United States and 40,000 worldwide each year) who would respond well.

It doesn't kill the cell that it hides in, but is dangerous enough that it can cause infections in individuals with an impaired immune system, such as patients who are receiving cancer treatment, who have pre-existing lung problems or whose immune systems are otherwise compromised.

«Patients with inoperable, early - stage lung cancer who receive stereotactic body radiation therapy have 40 % five - year survival rate.»

«It takes too long for patients who have suspected lung cancer to get final treatment, and too many patients skip vital steps needed to decide the best possible treatment,» said Dr. Osarogiagbon.

Nicolas Faris, MDiv and Raymond Osarogiagbon, MBBS led a group of researchers from Baptist Cancer Center and the University of Memphis in Tennessee, who reviewed hospital records for all patients who underwent surgery for suspected lung cancer at Baptist Memorial Hospital between January 2009 and JuneCancer Center and the University of Memphis in Tennessee, who reviewed hospital records for all patients who underwent surgery for suspected lung cancer at Baptist Memorial Hospital between January 2009 and Junecancer at Baptist Memorial Hospital between January 2009 and June 2013.

Using only patients who had surgery for suspected lung cancer, the researchers examined how long it took to begin care and what steps were taken to determine appropriate treatment.

«This technology [stereotactic body radiation] has been used successfully in both primary and metastatic lung and liver cancers, notably for patients who could not otherwise undergo surgery, with local control rates in excess of 90 percent» says Gan.

The booklet has been developed and reviewed by medical experts who treat patients with lung cancer.

The purpose of this study is to compare the effectiveness of daratumumab in combination with atezolizumab against atezolizumab alone in patients who have advanced non-small cell lung cancer (NSCLC) that has previously been treated.

This better understanding of BCX's molecular mechanism could lead to dietary recommendations for patients undergoing chemotherapy for lung cancer and for those who have survived, said Wang, who is also a professor at the Friedman School.

For example, a recent study of outcomes after lung cancer surgery demonstrated fewer complications and a higher success rate of cancerous node removal in patients who had their procedures performed by a thoracic surgeon, rather than a cardiac or general surgeon.

With the blood test, it is possible, at a very early stage of cancer (colon cancer, gastric cancer, lung cancer) to identify patients who are at high risk of developing life - threatening metastases.

Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.

Patients, especially those with larger tumors, who undergo thoracoscopic resections might have improved cancer specific survival compared with those undergoing SABR for early stage non-small lung cancer